Cadila buys out JV partner in Zydus BSV
Drugmaker Cadila Healthcare has acquired a 50% stake from fellow India-based biotech firm Bharta Serums and Vaccines in their joint venture firm-Zydus BSV Pharma, thus taking full control of the business, according to local media reports. Financial terms of the transaction were not disclosed.
Zydus BSV Pharma, which was founded in 2005 develops, manufactures and markets non-infringing and proprietary novel drug delivery system of approved anti-cancer agents for global markets. It also offers contract manufacturing capabilities based on its modern facility and experience in the oncology injectable product manufacturing area.
Zydus BSV’s finished dosage manufacturing plant is located at the pharmaceutical specific Special Economic Zone – Pharmez, strategically located in the pharma corridor of India, near Ahmedabad.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze